- Home
- EYEN vs KTTA Comparison
EYEN vs KTTA Comparison
Compare EYEN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- KTTA
- Stock Information
- Founded
- EYEN 2014
- KTTA 2020
- Country
- EYEN United States
- KTTA United States
- Employees
- EYEN N/A
- KTTA N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- KTTA Health Care
- Exchange
- EYEN Nasdaq
- KTTA Nasdaq
- Market Cap
- EYEN 2.9M
- KTTA 2.8M
- IPO Year
- EYEN 2018
- KTTA 2021
- Fundamental
- Price
- EYEN $15.82
- KTTA $0.75
- Analyst Decision
- EYEN Hold
- KTTA
- Analyst Count
- EYEN 4
- KTTA 0
- Target Price
- EYEN $2.00
- KTTA N/A
- AVG Volume (30 Days)
- EYEN 9.3M
- KTTA 168.4K
- Earning Date
- EYEN 08-11-2025
- KTTA 08-12-2025
- Dividend Yield
- EYEN N/A
- KTTA N/A
- EPS Growth
- EYEN N/A
- KTTA N/A
- EPS
- EYEN N/A
- KTTA N/A
- Revenue
- EYEN $67,063.00
- KTTA N/A
- Revenue This Year
- EYEN $7,680.45
- KTTA N/A
- Revenue Next Year
- EYEN $315.38
- KTTA N/A
- P/E Ratio
- EYEN N/A
- KTTA N/A
- Revenue Growth
- EYEN 663.82
- KTTA N/A
- 52 Week Low
- EYEN $0.85
- KTTA $0.70
- 52 Week High
- EYEN $124.80
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- EYEN 77.71
- KTTA 38.00
- Support Level
- EYEN $7.50
- KTTA $0.70
- Resistance Level
- EYEN $14.33
- KTTA $0.76
- Average True Range (ATR)
- EYEN 2.92
- KTTA 0.04
- MACD
- EYEN 0.87
- KTTA 0.01
- Stochastic Oscillator
- EYEN 90.98
- KTTA 27.26
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).